Nuvalent (NUVL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 16, 2026, with voting on director elections, executive compensation, and auditor ratification.
Stockholders of record as of April 20, 2026, are eligible to vote; Class A shares have voting rights, while Class B shares are non-voting except as required by law.
Proxy materials are distributed electronically to reduce costs and environmental impact, with paper copies available upon request.
Voting matters and shareholder proposals
Election of two Class II directors, Michael L. Meyers and Ron Squarer, for three-year terms expiring at the 2029 annual meeting.
Advisory vote on executive compensation (say-on-pay) and ratification of KPMG LLP as independent auditor for 2026.
Board recommends voting FOR all proposals; other business may be transacted as appropriate.
Procedures for submitting shareholder proposals and director nominations for the 2027 meeting are outlined, with deadlines and requirements specified.
Board of directors and corporate governance
Board consists of nine members divided into three staggered classes; following the meeting, the board will be reduced to eight members.
Majority of directors are independent per Nasdaq rules; CEO is not independent.
Chairperson and CEO roles are separated; board diversity and qualifications are emphasized in director selection.
Board committees include audit, compensation, and nominating/governance, each with defined responsibilities and independent membership.
Annual board and committee self-evaluations are conducted to ensure effectiveness.
Latest events from Nuvalent
- Director elections, executive pay, and auditor ratification up for vote at June 2026 meeting.NUVL
Proxy filing28 Apr 2026 - Pivotal NSCLC data and FDA filings set stage for commercial launches and global expansion.NUVL
44th Annual J.P. Morgan Healthcare Conference14 Apr 2026 - Pivotal data and regulatory progress position the pipeline for major NSCLC market impact.NUVL
Corporate presentation13 Apr 2026 - Strong clinical data and rapid enrollment position ROS1 and ALK drugs for global launch.NUVL
Leerink Global Healthcare Conference 20269 Mar 2026 - Lead oncology assets near approval, targeting major lung cancer markets with strong trial momentum.NUVL
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Lead oncology assets deliver strong efficacy and safety, targeting multi-billion dollar markets.NUVL
Corporate presentation27 Feb 2026 - $1.4B cash runway into 2029; NDA filings and commercial launch prep for key oncology assets in 2026.NUVL
Q4 202526 Feb 2026 - Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion.NUVL
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Global phase II studies advance in ALK and ROS1, with major data and strategy updates expected this year.NUVL
Jefferies 2024 Global Healthcare Conference1 Feb 2026